量研学術機関リポジトリ「QST-Repository」は、国立研究開発法人 量子科学技術研究開発機構に所属する職員等が生み出した学術成果(学会誌発表論文、学会発表、研究開発報告書、特許等)を集積しインターネット上で広く公開するサービスです。 Welcome to QST-Repository where we accumulates and discloses the academic research results(Journal Publications, Conference presentation, Research and Development Report, Patent, etc.) of the members of National Institutes for Quantum and Radiological Science and Technology.
Thank you very much for using our website. On the 11th of March 2019, this site was moved from our own network server to the JAIRO Cloud network server. If you previously bookmarked this site, that bookmark will no longer work. We would be grateful if you could bookmark the website again. Thank you very much for your understanding and cooperation.
No inhibitory effect on P-glycoprotein function at blood-brain barrier by clinical dose of clarithromycin: a human PET study with [11C]verapamil
利用統計を見る
To investigate the effects of the clinical dose of clarithromycin, a substrate of P-glycoprotein (P-gp), on P-gp function using positron emission tomography (PET) with [(11)C]verapamil. METHODS: Two PET scanning with [(11)C]verapamil were performed before and after administration of 400 mg/day of clarithromycin on each of four healthy male subjects. The rate constant of transfer from plasma to brain (K (1)) was estimated by integration plot method. RESULTS: K (1) values of [(11)C]verapamil before administration of clarithromycin were 0.042-0.070 mL/cm(3)/min (0.054 +/- 0.012) and those after administration were 0.037-0.066 mL/cm(3)/min (0.055 +/- 0.013). No significant change in K (1) values of [(11)C]verapamil was observed between before and after administration of clarithromycin (P = 0.85). CONCLUSION: K (1) values of [(11)C]verapamil were not changed by clinical dose administration of clarithromycin, suggesting that a clinical dose of clarithromycin does not affect P-gp function at the blood-brain barrier.